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Running Title: 
Comparison of Belatacept and Tacrolimus 
 
Abbreviations: 
aHR   Adjusted Hazard Ratio 
BMI   Body Mass Index 
BENEFIT Belatacept Evaluation of Nephroprotection and Efficacy as First-line 
Immunosuppression Trial 
BENEFIT-EXT  Belatacept Evaluation of Nephroprotection and Efficacy as First-line 
Immunosuppression Trial-EXTended criteria donors 
BPAR    Biopsy Proven Acute Rejection 
CI   Confidence Interval 
CNI   Calcineurin Inhibitor 
EBV    Epstein-Barr Virus 
ECD    Extended Criteria Donor 
eGFR    Estimated Glomerular Filtration Rate 
FDA   Federal Drug Administration 
cPRA   Calculated Panel Reactive Antibody 
DM   Diabetes Mellitus 
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HLA   Human Leukocyte Antigen 
KTR   Kidney Transplant Recipients 
LD   Lymphocyte Depleting 
MDRD   Modification of Diet in Renal Disease 
NODAT  New Onset Diabetes after Transplantation 
OPTN   Organ Procurement and Transplantation Network 
PTLD   Post-Transplant Lymphoproliferative Disease 
SCD   Standard Criteria Donors 
SRTR   Scientific Registry of Transplant Recipients 
SD   Standard Deviation 
 
Abstract 
The performance of belatacept in a real clinical setting has not been reported. A 
retrospective cohort study was conducted using registry data comparing one-year clinical 
outcomes between belatacept- and tacrolimus-treated adult kidney transplant recipients 
(KTR) from 6.1.2011 through 12.1.2014. Of 50 244 total patients, 417 received 
belatacept+tacrolimus, 458 received belatacept alone, and 49 369 received tacrolimus alone 
at discharge. In the overall study cohort, belatacept alone was associated with a higher risk 
for one-year acute rejection, with highest rates associated with non-lymphocyte depleting 
(LD) induction (aHR: 2.65; 95%CI: 1.90-3.70, P<.0001). There was no significant difference 
in rejection rates between belatacept+tacrolimus and tacrolimus alone. In KTR meeting 
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belatacept+tacrolimus and belatacept alone versus tacrolimus alone groups (mean eGFR: 
65.6 vs 60.4 vs 54.3 ml/min/1.73M2, respectively, P<.001). The incidence of new onset 
diabetes after transplantation was significantly lower with belatacept+tacrolimus and 
belatacept alone versus tacrolimus alone (1.7% vs 2.2% vs 3.8%, respectively, P=.01). 
Despite improved graft function and metabolic complications with belatacept alone, it may be 
advisable to add short-term tacrolimus the first year post-transplant and consider LD 
induction in high rejection risk patients, as the risk to benefit ratio allows. 
 
Introduction 
Standard maintenance immunosuppression regimens following kidney transplantation 
typically include a calcineurin inhibitor (CNI), either cyclosporine or tacrolimus, combined with 
mycophenolate mofetil and corticosteroids (1). CNI use over the past few decades has been 
associated with a reduction in the incidence of acute rejection (AR) and improvement in short-term 
allograft survival (2). However, while some clear gains have been made, improvements in long-term 
allograft survival have not been commensurate with those in the short-term (3). CNI nephrotoxicity 
has long been considered to be one of the numerous factors that contribute to long-term damage to 
transplant kidneys, although recent evidence implicates alloimmunity as a major determinant of late 
kidney allograft loss (4-6). In general, CNI withdrawal or avoidance strategies have not been very 
successful at preserving long-term graft function, and to date the CNIs still remain as the 
cornerstone of immunosuppression for renal transplant patients (7). However, in addition to being 
nephrotoxic, CNIs are significantly correlated with higher cardiometabolic complications, including 
post-transplant hypertension, diabetes, and hyperlipidemia (1). A long-term goal of the transplant 
community is to find an alternative immunosuppressive agent in lieu of CNIs that is not inherently 
nephrotoxic, protects adequately against alloimmunity, and does not increase cardiometabolic 
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Belatacept (Nulojix
®
; Bristol-Myers Squibb, Princeton, NJ) is a fusion receptor protein 
(CTLA4-Ig) developed as a selective co-stimulation blocker, with two amino acid substitutions in the 
CTLA4 binding domain that dramatically increase binding to CD80/CD86, resulting in effective 
inhibition of T-cell activation (8). The first phase III clinical trial, Belatacept Evaluation of 
Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT) was a one-year, 
randomized, active-controlled, multi-center trial conducted at 100 centers worldwide that targeted 
adult recipients of kidneys from living or standard criteria deceased donors (SCD) (9). The second 
phase III clinical trial, Belatacept Evaluation of Nephroprotection and Efficacy as First-line 
Immunosuppression Trial-EXTended criteria donors (BENEFIT-EXT), targeted adult recipients of 
extended criteria deceased donor (ECD) kidneys (10). Both trials showed non-inferior composite 
(patient death or graft loss) outcome and improved renal function and cardiovascular outcomes at 
one year in the belatacept-treated compared with the cyclosporine-treated patients. Belatacept 
patients experienced a higher yet non-inferior incidence of acute rejection episodes in the BENEFIT 
trial in the lower intensity FDA-approved dosage regimen compared with the cyclosporine-treated 
patients, whereas in the BENEFIT-EXT trial, the incidence of acute rejection was similar across 
groups. At seven years after transplantation in the BENEFIT trial, patient and graft survival and the 
mean eGFR were significantly higher with belatacept than with cyclosporine (11). 
Although FDA approval for the drug was received in June 2011, the experience regarding the 
utilization and outcomes of belatacept in a real clinical setting, where over 90% of renal transplant 
recipients in the U.S receive a tacrolimus-based regimen, have not yet been reported (2). In this 
study, the utilization pattern of belatacept in the U.S., as well as efficacy and safety outcomes 
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Materials and Methods 
Study Population 
A retrospective observational study based on registry data from the Scientific Registry of 
Transplant Recipients (SRTR) and approved by the University of Florida Institutional Review Board 
(Protocol #201400666) was conducted to compare utilization patterns and clinical outcomes 
between belatacept- and tacrolimus-treated kidney transplant recipients (KTR). SRTR data, including 
data on all donors, wait-listed candidates, and transplant recipients in the U.S, was collected by the 
members of the Organ Procurement and Transplantation Network (OPTN). The activities of the 
OPTN and SRTR contractors are administered by the Health Resources and Services Administration 
of the U.S. Department of Health and Human Services. The study included solitary KTR 18 years or 
older who received belatacept+tacrolimus-, belatacept- (without CNI, termed belatacept alone) or 
tacrolimus- (without belatacept, termed tacrolimus alone) based regimens at hospital discharge 
following transplant surgery after June 1st, 2011 and followed up through December 1st, 2014. 
Recipients were excluded if they received other organ transplants or used cyclosporine as a 
maintenance immunosuppressant drug at hospital discharge.  
 
Outcomes  
Patients were followed from the date of transplantation until death, graft loss (reported in 
SRTR as return to dialysis or re-transplantation), loss to follow-up, or 1 year after the transplant date, 
whichever came first. The primary outcomes for the study included: one-year composite patient 
death or graft loss and one-year incidence of biopsy-proven acute rejection (BPAR). The secondary 
outcomes included mean estimated glomerular filtration rate (eGFR) at 1 year using the modification 
of diet in renal disease (MDRD) equation (mL/min/1.73m2) (12, 13), the one-year incidence of new-
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lymphoproliferative disease (PTLD) and other new-onset malignancy. Primary and secondary 
outcomes within 1 year were compared between belatacept+tacrolimus-, belatacept alone- and 
tacrolimus alone-treated patients. Further analyses were conducted in the subgroups to investigate 
the association of drug regimens and outcomes in specific patient populations. 
 
Covariates 
Recipient demographic and clinical characteristics, as well as donor characteristics, were 
examined for the belatacept- and tacrolimus-treated groups. Recipient covariates in this study 
included: age, race (black versus others), gender, BMI (obese defined as BMI ≥30 kg/m2 versus non-
obese, BMI<30 kg/m2), pre-transplant cardiovascular disease, previous history of malignancy, 
previous kidney transplant, steroid use at hospital discharge, mycophenolate use at hospital 
discharge, cause of end stage renal disease (hypertension, diabetes, glomerulonephritis, polycystic 
kidney disease, and other), recipient panel reactive antibody (PRA), pre-transplant dialysis duration 
(>2 years, 0-2 years versus none), HLA mismatch (>3 versus ≤3), induction  with lymphocyte-
depleting (LD) agents (antithymocyte globulin or alemtuzumab), recipient insurance (private versus 
others), and recipient Epstein-Barr virus (EBV) serostatus (positive or negative). Donor characteristics 
were: age, gender, race, and graft types (living donor, SCD, or ECD). 
  
Center Effect 
Belatacept use was not uniform in U.S. transplant centers. Only 25% of U.S. transplant 
centers had begun to use belatacept prior to December 01, 2014. Fifty seven percent of KTR who 
received belatacept by that date were transplanted at just one of the sixty U.S. centers using the 
drug, which was named “major belatacept center”. Based on SRTR discharge immunosuppression 
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center were treated with a combined regimen of belatacept+tacrolimus. The other 59 transplant 
centers in this study, whose rate of belatacept use ranged from 0.1% to 15.8%, were grouped 
together and named “other belatacept centers”. The risks associated with the major and other 
belatacept center types was defined as a co-variate “center effect” for the purpose of adjustments in 
the multivariable models. 
 
Subgroup Analysis 
  Subgroup analyses were performed to investigate the associations of different induction 
drugs (LD or non-LD) as part of each immunosuppression regimen with the clinical outcomes related 
to belatacept use. Multivariate analyses were performed for the two primary outcomes in the entire 
study cohort, as well as for the two different induction groups.  To compare the current study results 
with those from the two major belatacept clinical trials, BENEFIT and BENEFIT-EXT, the primary 
clinical outcomes were also analyzed in patients who met the same inclusion and had none of the 
exclusion criteria specified in these trials. Specifically, those recipients meeting criteria for the 
BENEFIT trial (living donor or SCD, with cold ischemia time < 24h and PRA < 50% for first transplants 
and < 30% for re-transplants) were designated as BENEFIT-eligible recipients, while those recipients 
meeting criteria for the BENEFIT-EXT trial (donors ≥60 years old; or donors ≥50 years old who had at 
least two other risk factors of hypertension, death from cerebrovascular accident, or serum 
creatinine >1.5mg/dL; or cold ischemia time of ≥24 hours; or donation after cardiovascular death) 
were designated as BENEFIT-EXT-eligible recipients. High PRA KTR, defined as first-time transplants 
with a PRA ≥50% or re-transplants with a PRA ≥30% (exclusion criteria for both BENEFIT and 
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Statistical Analysis 
Categorical variables were compared between the comparison groups using chi-square tests, 
whereas continuous variables were compared using student t-tests for two-group comparison and F 
test for more than two-group comparison. Multivariate Cox proportional hazards model was used to 
assess the hazard ratio for the first occurrence of patient death or graft loss or BPAR within the first 
post-transplant year comparing three different regimens. The assumption of proportional hazards 
underlying the Cox model was tested and confirmed by visually inspecting the complementary log-
log survival plots for the primary explanatory variables and by examining the Schoenfeld residual 
plots. To fit the multivariate model, a univariate analysis was first conducted with the major 
exposure variable and then with each covariate added one at a time to examine the change of the 
estimate of the major exposure variable. The covariates that modified the estimate of the major 
exposure variable over 3% were kept in the final multivariate model. All analyses were conducted 





A total of 50 244 adult recipients underwent solitary kidney transplantation from June 1, 
2011 through December 1, 2014.  Based on immunosuppression reported at the time of 
discharge, 875 KTR received a belatacept regimen (417 concomitantly with tacrolimus and 
458 on belatacept alone).  A total of 49 369 KTR received tacrolimus but not belatacept 
(tacrolimus alone). At 12 months post-transplant, 54%, 57%, and 66% of patients in the 
belatacept+tacrolimus, belatacept alone, and tacrolimus alone groups, respectively, had 










This article is protected by copyright. All rights reserved. 
patients in these groups maintained the discharge drug regimens at one-year follow up, 
respectively. Out of 417 belatacept+tacrolimus-treated patients at 1 year, 123 remained on 
belatacept+tacrolimus at 12 months, 71 were treated with belatacept alone, 26 were 
treated with tacrolimus alone, and 4 were switched to other immunosuppressants. None of 
belatacept+tacrolimus-treated patients in “other belatacept centers” maintained the 
discharge drug regimen at 12 months.  
The demographic and clinical characteristics of the belatacept+tacrolimus-, 
belatacept alone-, and tacrolimus alone-treated patients are compared in Table 1. Most of 
the P values for the comparisons between cohorts appear significant due to the large 
sample size. However, only the following factors achieved a clinically meaningful difference 
of >10% between cohorts: induction drug use, EBV seropositivity, recipient PRA, recipient 
race, steroid use and transplant center. Patients who received a belatacept+tacrolimus 
regimen were more likely than belatacept-alone and tacrolimus-alone patients to have 
received a transplant at the major belatacept center (90% vs 28% vs 0.43%, P<.0001, 
respectively). Compared to belatacept alone-treated patients, belatacept+tacrolimus-
treated patients were also more likely to be sensitized (PRA higher than 20%: 37% vs 21%, 
respectively; P<.0001), be African American (49% vs 23%, P<.0001), and be retransplants 
(10% vs 5%, P=.0025), while less likely to have received LD induction drugs (7% vs 51%, 
P<.0001). Thus, aside from being discharged more often on steroids (92% vs 77%, P<.0001), 
the patients who received the belatacept+tacrolimus regimen had overall more baseline 
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Patient/graft survival 
All patient and graft survival outcomes data are listed in Table 2. The rates of 
one-year patient death, death with functioning graft, death-censored graft loss, and 
composite patient death or graft loss in the two belatacept (belatacept+tacrolimus 
and belatacept alone) regimens were not significantly different than those of the 
tacrolimus alone group.  
 
Acute rejection 
Figure 1a compares the unadjusted one-year BPAR rates of the overall study 
population, BENEFIT-eligible recipients, and BENEFIT-EXT-eligible recipients. The 
rates of one-year BPAR were numerically similar between belatacept+tacrolimus- 
and belatacept alone-treated KTR in the overall study population (16.8% vs 18.8%, 
P=.44), BENEFIT-eligible patients (15.7% vs 16.7%, P=.75), and BENEFIT-EXT-
eligible patients (17.1% vs 19.1%, P=.71). However, these rejection rates (in the 
belatacept+tacrolimus- and belatacept alone-treated KTR) were significantly higher 
than those in the tacrolimus alone-treated KTR across the three comparison groups 
(6.5% in all patients, 6.0% in BENEFIT-eligible, 6.6% in BENEFIT-EXT-eligible 
patients).  
Figure 1b compares the one-year BPAR rates between treatment groups 
under LD and non-LD induction regimens. The use of LD induction drugs was 
associated with lower one-year BPAR rates in the KTR who received belatacept-
alone (14.6% vs 23.1%, P=.02), with no significant difference observed in 
belatacept+tacrolimus recipients (20.7% vs 16.5%, P=.56). Subgroup analysis in 
belatacept-alone treated KTR meeting BENEFIT-EXT criteria demonstrated a high 
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receiving LD induction (11.9%, P=.03). The lowest rejection rates were observed in 
the tacrolimus-alone group with either induction agent (6.2% in LD induction, and 
7.1% in non-LD induction).  
High PRA recipients, who were excluded from the BENEFIT and BENEFIT-EXT clinical trials, 
experienced more one-year BPAR in the two belatacept groups than in the tacrolimus alone group 
(19.7% vs 36.4% vs 8.3% for belatacept+tacrolimus, belatacept alone, and tacrolimus alone, 
respectively, P<.0001). The highest rate of one-year BPAR occurred in the belatacept alone-treated 
high PRA patients who received non-LD induction (43%).  
Table 3 contains the adjusted hazard ratios for BPAR within one year of 
transplantation with belatacept+tacrolimus vs tacrolimus alone treatments, and 
belatacept alone vs tacrolimus alone treatments, and belatacept+tacrolimus vs 
belatacept alone treatments. Compared with tacrolimus alone, a significantly 
increased risk of BPAR associated with belatacept alone use within the first year was 
identified in the overall study cohort (aHR: 2.36; 95%CI: 1.82-3.05, P<.0001), 
BENEFIT-eligible recipients (aHR: 2.51, 95%CI: 1.79-3.52, P<.0001), BENEFIT-
EXT-eligible recipients (aHR: 1.74, 95%CI: 1.06-2.85, P<.03), recipients who 
received LD induction (aHR: 1.86; 95%CI: 1.20-2.90, P=.006), and recipients who 
received non-LD induction (aHR: 2.65; 95%CI: 1.90-3.70, P<.0001). Compared with 
tacrolimus alone, belatacept+tacrolimus treatment was not significantly associated 
with an increased risk of BPAR within 1 year in the overall study cohort or subgroup 
analyses, although the BPAR risk was suggestively higher in recipients who received 
LD induction (aHR: 2.35; 95%CI: 0.94 – 5.90, P=.07). Furthermore, in All Recipients 
and Recipients Used Non LD Induction, the risk of rejection was lower with 
belatacept + tacrolimus treatment compared to belatacept alone, and was 
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Recipients. Only in the Recipients Used LD Induction Drugs group did there not 
appear to be a benefit of adding tacrolimus of belatacept. Multivariate analysis could 
not be performed on the high PRA group due to insufficient patient numbers.  
 
Renal function   
Figure 2 shows the comparison of eGFR at 1 year between the three drug regimens for all 
recipients, BENEFIT-eligible recipients, and BENEFIT-EXT-eligible recipients. The eGFR was 
significantly higher in the belatacept+tacrolimus and belatacept alone-treated recipients than in the 
tacrolimus alone-treated recipients in all recipients (64.1 vs 63.5 vs 58.6 mL/min/1.73m2, 
respectively, P=.0015) and in the BENEFIT-EXT-eligible group (65.6 vs 60.4 vs 54.3 mL/min/1.73m2, 
respectively, P=.0003), although no significant differences were seen in the BENEFIT-eligible 
recipients (62.6 vs 63 vs 60 mL/min/1.73m2, respectively, P=.13). There were no significant 
differences in eGFR between belatacept+tacrolimus and belatacept alone patients in all subgroups.  
 
New onset diabetes and malignancy  
Figure 3 compares the incidences of NODAT, de novo PTLD, and other new 
onset malignancy between the three-drug regimens for all recipients based on data 
at 1 year post-transplant follow up. The incidence of NODAT was significantly lower 
in the belatacept+tacrolimus and belatacept alone groups than in the tacrolimus 
alone group (1.7% vs 2.2% vs 3.8%, respectively, P=.01). The incidences of de novo 
PTLD or other new onset malignancy were similar in the three comparison groups. 
None of the belatacept-treated patients who developed PTLD were EBV 
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Discussion 
In the current study, the absolute rates of one-year BPAR in belatacept alone-
treated patients were similar to those reported in the two clinical trials (16.7% and 
18.6% in BENEFIT-eligible and BENEFIT-EXT-eligible, respectively, compared to 
17% and 17.7% for the BENEFIT and BENEFIT-EXT trials, respectively), although 
the belatacept alone-treated patients had significantly higher BPAR rates compared 
to the tacrolimus alone-treated recipients in all study groups. Furthermore, in 
belatacept alone-treated recipients treated with a non-LD induction drug, the 
absolute one-year BPAR rate was higher at 23.1%. Treatment with a non-LD 
induction drug but addition of tacrolimus to the belatacept regimen 
(belatacept+tacrolimus-treated recipients) at discharge reduced the one-year BPAR 
rejection rate down to 16.5%. The belatacept+tacrolimus-treated patients who 
received LD induction were at higher risk for rejection than belatacept alone-treated 
patients, which likely explains this group having the highest absolute rejection rate in 
all recipients receiving LD induction (20.7%). Indeed, multivariate analysis 
demonstrated no significant difference in hazard ratios for rejection between 
belatacept+tacrolimus and tacrolimus alone patients with LD induction and in all 
groups studied. However, BPAR rates in the belatacept+tacrolimus-treated patients 
who received LD induction are suggestively higher than in those treated with 
tacrolimus alone, although the group comprised only 29 patients. Further 
investigation with larger sample size is clearly needed to be able to draw any further 
conclusions. In the real clinical setting, there are often high PRA patients, who were 
excluded from the clinical trials. In fact, the highest absolute rate of rejection was 
observed in the high PRA patients who did not receive LD induction (43%). Taken in 
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belatacept alone and strong consideration of LD induction or addition of tacrolimus 
for the first year post-transplant, especially in recipients with a high baseline risk for 
rejection.  
At 12 months, renal function was superior in patients receiving belatacept versus 
cyclosporine in both the BENEFIT  and BENEFIT-EXT  trials (9, 10). In the current study, renal function 
was no different between belatacept+tacrolimus, belatacept alone-, and tacrolimus-treated patients 
at 12 months in the patients meeting BENEFIT criteria. However, in those patients meeting BENEFIT-
EXT criteria, renal function was significantly greater in belatacept+tacrolimus- and belatacept alone- 
versus tacrolimus alone-treated patients. In patients meeting BENEFIT or BENEFIT-EXT criteria, renal 
function in the tacrolimus alone-treated patients (60 and 54 mL/min/1.73M2, respectively) was 
observed to be numerically higher than that reported for the cyclosporine-treated patients in the 
BENEFIT and BENEFIT-EXT trials (50 and 45 mL/min/1.73M2, respectively). 
 In both the BENEFIT and BENEFIT-EXT trials, belatacept was associated with significant 
improvement in cardiometabolic complications of blood pressure and lipid control compared to 
cyclosporine, and in the BENEFIT-EXT trial, a significant reduction in incidence of NODAT was also 
reported. In the current study, only the incidence of NODAT could be assessed, since the SRTR 
database does not contain measurements for blood pressure or lipid levels. In both belatacept-
treated groups, the one-year incidence of NODAT was significantly lower in comparison to 
tacrolimus alone-treated patients. It therefore does not appear that tacrolimus as used in the 
belatacept+tacrolimus group incurs the same risk for NODAT as with the standard usage of the drug, 
which along with the eGFR results, leads one to speculate that the combined regimen involved lower 
goal tacrolimus levels, especially since steroid use was significantly higher in this group.  
In the BENEFIT and BENEFIT-EXT trials, 1.0% of patients receiving the approved dosage 
developed PTLD during the first year compared to 0.2% of those who received cyclosporine, with 
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treated (>94% EBV seropositive) versus 0.13% of tacrolimus alone-treated patients developed PTLD 
in this same time frame, which may reflect greater awareness among clinicians of the role EBV 
seropositivity plays in the proper selection of belatacept candidates to decrease this risk.  A total of 9 
other new onset malignancies occurred during one-year follow up in belatacept+tacrolimus (0.5%) 
and belatacept alone groups (1.5%), which were not statistically different with the tacrolimus alone 
group (1.2%).  
The major strength of this study is the large study population available through use of the 
nationwide SRTR dataset, which enhances generalizability of the study findings and provides the 
power for precision of the statistical analyses. The limitations of this study include missing post-
transplant follow up data for the primary outcomes and the lack of data on important secondary 
outcomes, such as blood pressure, lipid panel measurements, and infection diagnoses. The 
immunosuppressant drug dosage and trough levels are not collected by the SRTR, and similarly, the 
types of acute rejection cannot be ascertained. Information is also lacking on the presence of donor 




Despite a higher rate of acute rejection, belatacept alone use was associated with non-
inferior effects on composite patient death or one-year graft loss outcome compared with 
tacrolimus alone use in a real clinical setting. The acute rejection rates were particularly high in 
those recipients with high PRA who did not receive LD induction. Belatacept use resulted in 
significantly higher renal function at 1 year compared to tacrolimus in BENEFIT-EXT eligible 
recipients of kidneys from marginal donors. It is unknown at this time whether the superior graft 
function at 1 year will translate into better long-term graft survival in this cohort. Finally a 
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tacrolimus during parts of the first year. It may be advisable to add short-term tacrolimus to 
belatacept during the first year post-transplant and consider LD induction in all but the lowest risk 
patients, as the risk to benefit ratio allows.  
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Figure Legends 
Figure 1. (A) Comparison of unadjusted one-year BPAR rates between three drug regimens in All 
Recipients, BENEFIT-eligible Recipients, and BENEFIT-EXT-eligible Recipients. The rates of one-year 
BPAR were numerically similar between belatacept+tacrolimus- and belatacept alone- treated KTR in 
the overall study population, BENEFIT-eligible patients, and BENEFIT-EXT-eligible patients. However, 
these rejection rates (in the belatacept+tacrolimus- and belatacept alone-treated KTR) were 
significantly higher than those in the tacrolimus alone-treated KTR across the three comparison 
groups. BPAR, biopsy-proven acute rejection; KTR, kidney transplant recipients. (B) Comparison of 
one-year unadjusted BPAR rates between three drug regimens in patients receiving lymphocyte-
depleting and non lymphocyte-depleting induction. The use of lymphocyte depleting induction drugs 
was associated with lower one-year BPAR rates in the recipients who received belatacept-alone, 
whereas these rates were higher in belatacept+tacrolimus recipients. The lowest rejection rates 
were observed in the tacrolimus-alone group with either induction agent. BPAR, biopsy-proven 
acute rejection; KTR, kidney transplant recipients. 
 
Figure 2. Comparison of eGFR at 1 year between three drug regimens in All Recipients, BENEFIT-
eligible Recipients, and BENEFIT-EXT-eligible Recipients. The eGFR was significantly higher in the 
belatacept+tacrolimus or belatacept alone-treated recipients than in the tacrolimus alone-treated 
recipients in all recipients and in the BENEFIT-EXT-eligible group, although no significant differences 
were seen in the BENEFIT-eligible recipients. There were no significant differences in eGFR between 
belatacept+tacrolimus and belatacept alone in either subgroup. KTR, kidney transplant recipients; 
eGFR, estimated glomerular filtration rate. 
 
Figure 3. Comparison of metabolic and malignancy outcomes at 1 year 
between three drug regimens. The incidence of NODAT was significantly lower in 
the two belatacept groups than in the tacrolimus-alone group. The incidences of de 
novo PTLD or other new onset malignancy were similar in the three comparison 
groups. KTR, kidney transplant recipients; NODAT, new onset diabetes after 
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Recipient Age, Years, Mean ± SD 51.5 ± 13.1 53.7 ± 13.9 51.9 ± 13.6 .017 
Recipient African American Race, 






12 283 (25) 
<.000
1 
Recipient Female Gender, N (%) 174 (42) 155 (34) 19 091 (39) .05 
Dialysis Length Pre-transplant, N 
(%)                                
Preemptive 
                                  0-2 Years 











14 334 (29) 
25 850 (52) 
<.000
1 
Recipient BMI>30, N (%) 128 (31) 163 (36) 16906 (34) .0017 







107 (23)  
124 (27) 
 
10 987 (22) 
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Glomerulonephritis 








10 661 (22) 
4792 (10) 
9949 (20) 
Donor Age, Years, Mean ± SD 39.0 ± 15.6 43.6 ± 14.6 39.5 ± 14.9 <.000
1 
Donor Female Gender, N (%) 227 (54) 236 (52) 23 192 (47) .0016 
Donor African American Race, N (%) 118 (28) 67 (15) 6605 (13) <.000
1 
Donor Type by OPTN, N (%) 
Living Donor 
Standard Criteria Donor 










16 408 (33) 





















29 253 (59) 




Donor Death Due to Cerebrovascular 
Accident, N (%) 
49 (18) 43 (16) 4709 (14) .19 
Donor Hypertension, N (%) 91 (22) 107 (23) 10 031 (20) .21 
Donor Diabetes, N (%) 154 (37) 205 (45) 19 003 (38) .02 
















30 827 (68) 
5 402 (12) 
3 861 (9) 
5 030 (11) 
<.000
1 
Recipient Epstein-Barr Virus 
Seropositivity, N (%) 
410 (98) 431 (94) 38 011 (77) <.000
1 
HLA Mismatch >3, N (%) 286 (69) 293 (64) 32 008 (65) <.000
1 
Cold Ischemia Time, Hours, 
Mean ± SD  
11.4 ± 8.8 12.1 ± 10.0 12.4 ± 10.3 .09 
Delayed Graft Function, N (%) 82 (20) 91 (20) 8554 (17) .17 
Induction with LD Agents, N (%) 29 (7) 233 (51) 33 228 (67) <.000
1 
Steroid Use at Discharge, N (%) 384 (92) 354 (77) 34 633 (70) <.000
1 
Mycophenolate Mofetil Use at 
Discharge, N (%) 
411 (99) 423 (92) 47 963 (97) <.001 
Sirolimus Use at Discharge, N 
(%) 
0 (0) 22 (4.8) 470 (1) <.000
1 
Recipient with Cardiovascular 
Disease, N (%) 
44 (11) 56 (12) 4578 (9) .02 
Recipient Previous Malignancy, N 
(%) 
35 (8) 50 (11) 3452 (7) .003 
Recipient Primary Insurance, 
Private, N (%)    
110 (26) 170 (37) 17 476 (35) <.000
1 
Recipients with Previous Kidney 
Transplant, N (%)    
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Recipient Physical Capacity with 
Limitation, N (%) 
385 (92) 402 (88) 39 969 (81) <.000
1 
Recipient Serum Creatinine at 
Discharge, Mean ± SD 
3.1 ± 2.6 3.2 ± 3.0 2.9 ± 2.6  .01 
Kidney Transplant Center, N (%) 










Mean Follow Up (Months),  
Mean ± SD 
8.7 ± 7.0 10 ± 9 12.9 ± 10.2 <.000
1 


























*:  OPTN Extended Criteria Donor, defined as donors ≥60 years old; or donors ≥50 
years old and who had at least two other risk factors (hypertension, death from 
cerebrovascular accident, or serum creatinine >1.5mg/dL). 
**: (i) BENEFIT-eligible Donor, defined as living donors and non extended criteria 
deceased donors with cold ischemia time of <24 hours. Excluded were donation 
after cardiac death deceased donors, first-time transplants with a PRA ≥50%, and 
re-transplants with a PRA ≥30%.  
(ii) BENEFIT-EXT-eligible Donor, defined as donors ≥60 years old; or donors ≥50 
years old and who had at least two other risk factors (hypertension, death from 
cerebrovascular accident, or serum creatinine >1.5mg/dL); or cold ischemia time 
of ≥24 hours; or donation after cardiovascular death. 
(iii) High PRA Recipients are first-time patients with a panel reactive antibody 
≥50% or re-transplants with a panel reactive antibody ≥30%. 
***: Column percent adds to 100%.  
     KTR, kidney transplant recipients; SD, standard deviation; BMI, body mass index; 
ESRD, end stage renal disease; PRA, panel reactive antibody; HLA, human 
leukocyte antigen; LD, lymphocyte-depleting; OPTN, Organ Procurement and 
Transplantation Network. 
 
Table 2: Patient/Graft Survival in All Recipients, BENEFIT-eligible Recipients, BENEFIT-EXT-eligible 
Recipients, and High PRA Recipients. 
Patient 
Groups 











Number of Patients N=417 N=458 N=49 369 
Graft Loss or Death, N (%) 13 (3.1) 17 (3.7) 2002 (4.1) 
Death Censored Graft Loss 6 (1.4) 7 (1.5) 1067 (2.2) 
Death 9 (2.2) 12 (2.6) 1154 (2.3) 














Number of Patients N=236 N=299 N=29 253 
Graft Loss or Death, N (%) 7 (3) 10 (3.3) 894 (3.1) 
Death Censored Graft Loss 3 (1.3) 4 (1.3) 453 (1.6) 
Death 4 (1.7) 7 (2.3) 530 (1.8) 
Death with Functioning Graft 4 (1.7) 6 (2.0) 466 (1.6) 
BENEFIT-
EXT- eligible  
Recipients*
* 
Number of Patients N=105 N=126 N=13 310 
Graft Loss or Death, N (%) 4 (3.8) 6 (4.8) 842 (6.3) 
Death Censored Graft loss 2 (1.9) 2 (1.6) 463 (3.5) 
Death 3 (2.9) 5 (4.0) 486 (3.7) 




Number of Patients N=76 N=33 N=6806 
Graft Loss or Death, N (%) 2 (2.6) 1 (3.0) 266 (3.9) 
Death Censored Graft Loss 1 (1.3) 1 (3.0) 151 (2.2) 
Death 2 (2.6) 0 (0.0) 138 (2.0) 
Death with Functioning Graft 1 (1.3) 0 (0) 120 (1.8) 
* BENEFIT-eligible Donor, defined as living donors and non extended criteria 
deceased donors with cold ischemia time of <24 hours. Excluded were donation 
after cardiac death deceased donors, first-time transplants with a PRA ≥50%, and 
re-transplants with a PRA ≥30%.  
 
**BENEFIT-EXT-eligible Donor, defined as donors ≥60 years old; or donors ≥50 years 
old and who had at least two other risk factors (hypertension, death from 
cerebrovascular accident, or serum creatinine >1.5mg/dL); or cold ischemia time of 
≥24 hours; or donation after cardiovascular death 
***High PRA Recipients are first-time patients with a panel reactive antibody ≥50% or 
re-transplants with a panel reactive antibody ≥30% 
PRA, panel reactive antibody.  
Table 3. Adjusted hazard ratios for one-year BPAR  
















All Recipients 1.33 
(0.93 – 1.90, 
P=.12) 
2.36 
(1.82 – 3.05, 
P<.0001) 
0.54 




Induction Drugs  
2.35 
(0.94 – 5.90, 
P=.07) 
1.86 
(1.20 – 2.90, 
P=.006) 
1.50 
(0.51 – 4.41, 
P=0.47) 




(0.93 – 2.08, 
P=.11) 
2.65 
(1.90 – 3.70, 
P<.0001) 
0.50 
(0.32 – 0.76, 
P=0.001) 
BENEFIT-eligible Recipients 1.65 
(0.98 – 2.78, 
P=.06) 
2.51 
(1.79 – 3.52, 
P<.0001) 
0.64 





(0.38 – 1.40, 
P=.35) 
1.74 
(1.06 – 2.85, 
P=.027) 
0.41 
(0.18 – 0.96, 
P=0.04) 
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Other covariates adjusted in the model include: recipient age, race, gender, steroid use at hospital 
discharge, mycophenolate mofetil use at hospital discharge, panel reactive antibody, pre-transplant 
dialysis duration, HLA mismatch, recipient insurance, and recipient Epstein-Barr virus infection. 
Donor characteristics were: donor age, and donor types.  
Induction with lymphocyte-depleting agents was only adjusted in the multivariate model for All 
Recipients, BENEFIT-eligible Recipients, and BENEFIT-EXT-eligible recipients. For the subgroup 
analyses in Patients used Lymphocyte-Depleting Induction Drugs or Recipients Used Non 
Lymphocyte-Depleting Induction Drugs, choice of induction agent was not adjusted in the 
multivariate model.  
BPAR, biopsy proven acute rejection; CI, confidence interval. 
 
 
Figure 1. a) Comparison of unadjusted one-year BPAR rates between three drug regimens in All 
Recipients, BENEFIT-eligible Recipients, and BENEFIT-EXT-eligible Recipients. The rates of one-year 
BPAR were numerically similar between belatacept+tacrolimus- and belatacept alone- treated KTR in 
the overall study population, BENEFIT-eligible patients, and BENEFIT-EXT-eligible patients. However, 
these rejection rates (in the belatacept+tacrolimus- and belatacept alone-treated KTR) were 
significantly higher than those in the tacrolimus alone-treated KTR across the three comparison 
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Figure 1. b) Comparison of one-year unadjusted BPAR rates between three drug regimens in 
patients receiving lymphocyte-depleting and non lymphocyte-depleting induction. The use of 
lymphocyte depleting induction drugs was associated with lower one-year BPAR rates in the 
recipients who received belatacept-alone, whereas these rates were higher in belatacept+tacrolimus 
recipients. The lowest rejection rates were observed in the tacrolimus-alone group with either 
induction agent. BPAR, biopsy-proven acute rejection; KTR, kidney transplant recipients. 
 
 
Figure 2. Comparison of eGFR at 1 year between three drug regimens in All Recipients, BENEFIT-
eligible Recipients, and BENEFIT-EXT-eligible Recipients. The eGFR was significantly higher in the 
belatacept+tacrolimus or belatacept alone-treated recipients than in the tacrolimus alone-treated 
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were seen in the BENEFIT-eligible recipients. There were no significant differences in eGFR between 
belatacept+tacrolimus and belatacept alone in either subgroup. KTR, kidney transplant recipients; 
eGFR, estimated glomerular filtration rate. 
 
 
Figure 3. Comparison of metabolic and malignancy outcomes at 1 year between three drug 
regimens. The incidence of NODAT was significantly lower in the two belatacept groups than in the 
tacrolimus-alone group. The incidences of de novo PTLD or other new onset malignancy were similar 
in the three comparison groups. KTR, kidney transplant recipients; NODAT, new onset diabetes after 
transplantation; PTLD, post-transplant lymphoproliferative disease; KTR, kidney transplant 
recipients. 
 
 
